Glucagon-like receptor 1 agonists and DPP-4 inhibitors: potential therapies for the treatment of stroke

J Cereb Blood Flow Metab. 2015 May;35(5):718-23. doi: 10.1038/jcbfm.2015.17. Epub 2015 Feb 11.

Abstract

During the past decades, candidate drugs that have shown neuroprotective efficacy in the preclinical setting have failed in clinical stroke trials. As a result, no treatment for stroke based on neuroprotection is available today. The activation of the glucagon-like peptide 1 receptor (GLP-1) for reducing stroke damage is a relatively novel concept that has shown neuroprotective effects in animal models. In addition, clinical studies are currently ongoing. Herein, we review this emerging research field and discuss the next milestones to be achieved to develop a novel antistroke therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Dipeptidyl Peptidase 4 / metabolism*
  • Disease Models, Animal
  • Glucagon-Like Peptide-1 Receptor
  • Humans
  • Neuroprotective Agents / therapeutic use*
  • Receptors, Glucagon / agonists*
  • Receptors, Glucagon / metabolism
  • Serine Proteinase Inhibitors / therapeutic use*
  • Stroke* / drug therapy
  • Stroke* / metabolism
  • Stroke* / pathology

Substances

  • GLP1R protein, human
  • Glucagon-Like Peptide-1 Receptor
  • Neuroprotective Agents
  • Receptors, Glucagon
  • Serine Proteinase Inhibitors
  • DPP4 protein, human
  • Dipeptidyl Peptidase 4